{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:00:41Z","timestamp":1790892041686,"version":"4.1.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10637-025-01562-3","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T14:29:10Z","timestamp":1756823350000},"page":"1086-1108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Advanced strategies to overcome multidrug resistance in cancer therapy: progress in P-glycoprotein inhibitors, drug delivery, and personalized medicine"],"prefix":"10.1007","volume":"43","author":[{"given":"Ankitha","family":"Harish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Deepika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedamurthy","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash S.","family":"Goudanavar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"issue":"9","key":"1562_CR1","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.3390\/ijms21093233","volume":"21","author":"K Bukowski","year":"2020","unstructured":"Bukowski K, Kciuk M, Kontek R (2020) Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci 21(9):3233","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1562_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3(4):524","journal-title":"JAMA Oncol"},{"key":"1562_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114643","volume":"162","author":"C Duan","year":"2023","unstructured":"Duan C, Yu M, Xu J, Li BY, Zhao Y, Kankala RK (2023) Overcoming cancer multi-drug resistance (MDR): reasons, mechanisms, nanotherapeutic solutions, and challenges. Biomed Pharmacother 162:114643","journal-title":"Biomed Pharmacother"},{"key":"1562_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.addr.2014.05.017","volume":"75","author":"C Loira-Pastoriza","year":"2014","unstructured":"Loira-Pastoriza C, Todoroff J, Vanbever R (2014) Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev 75:81\u201391","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"1562_CR5","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1021\/acsbiomaterials.7b00569","volume":"3","author":"RK Kankala","year":"2017","unstructured":"Kankala RK, Liu CG, Chen AZ, Wang SB, Xu PY, Mende LK et al (2017) Overcoming multidrug resistance through the synergistic effects of hierarchical pH-sensitive ROS-generating nanoreactors. ACS Biomater Sci Eng 3(10):2431\u20132442","journal-title":"ACS Biomater Sci Eng"},{"issue":"S1","key":"1562_CR6","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1038\/bjc.2015.48","volume":"112","author":"RD Neal","year":"2015","unstructured":"Neal RD, Tharmanathan P, France B, Din NU, Cotton S, Fallon-Ferguson J et al (2015) Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer 112(S1):S92-107","journal-title":"Br J Cancer"},{"key":"1562_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jconrel.2022.09.065","volume":"352","author":"T Li","year":"2022","unstructured":"Li T, Li J, Chen Z, Zhang S, Li S, Wageh S et al (2022) Glioma diagnosis and therapy: current challenges and nanomaterial-based solutions. J Controlled Release 352:338\u2013370","journal-title":"J Controlled Release"},{"issue":"4","key":"1562_CR8","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/ddr.21918","volume":"83","author":"A Husain","year":"2022","unstructured":"Husain A, Makadia V, Valicherla GR, Riyazuddin M, Gayen JR (2022) Approaches to minimize the effects of P-glycoprotein in drug transport: a review. Drug Dev Res 83(4):825\u2013841","journal-title":"Drug Dev Res"},{"issue":"7","key":"1562_CR9","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.3390\/cancers13071538","volume":"13","author":"SCE Wright","year":"2021","unstructured":"Wright SCE, Vasilevski N, Serra V, Rodon J, Eichhorn PJA (2021) Mechanisms of resistance to PI3K inhibitors in cancer: adaptive responses, drug tolerance and cellular plasticity. Cancers 13(7):1538","journal-title":"Cancers"},{"issue":"6","key":"1562_CR10","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/life12060897","volume":"12","author":"C Karthika","year":"2022","unstructured":"Karthika C, Sureshkumar R, Zehravi M, Akter R, Ali F, Ramproshad S et al (2022) Multidrug resistance of cancer cells and the vital role of P-glycoprotein. Life 12(6):897","journal-title":"Life"},{"issue":"7","key":"1562_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2174\/0113894501335548250123072644","volume":"26","author":"R Goyal","year":"2025","unstructured":"Goyal R, Kaur G, Malik DS, Singh S, Dua K, Singh D et al (2025) Assessing anti-acne potentials via in vitro, ex vivo, and in vivo models: a comprehensive approach. Curr Drug Targets 26(7):435\u2013453","journal-title":"Curr Drug Targets"},{"issue":"1","key":"1562_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2174\/1389450122666210412125018","volume":"23","author":"MM Estevinho","year":"2022","unstructured":"Estevinho MM, Fernandes C, Silva JC, Gomes AC, Afecto E, Correia J et al (2022) Role of ATP-binding cassette transporters in sorafenib therapy for hepatocellular carcinoma: an overview. Curr Drug Targets 23(1):21\u201332","journal-title":"Curr Drug Targets"},{"issue":"7","key":"1562_CR13","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3390\/cancers13071686","volume":"13","author":"LN Davis","year":"2021","unstructured":"Davis LN, Sherbenou DW (2021) Emerging therapeutic strategies to overcome drug resistance in multiple myeloma. Cancers 13(7):1686","journal-title":"Cancers"},{"issue":"7","key":"1562_CR14","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1039\/C6TB03146C","volume":"5","author":"RK Kankala","year":"2017","unstructured":"Kankala RK, Tsai PY, Kuthati Y, Wei PR, Liu CL, Lee CH (2017) Overcoming multidrug resistance through co-delivery of ROS-generating nano-machinery in cancer therapeutics. J Mater Chem B 5(7):1507\u20131517","journal-title":"J Mater Chem B"},{"issue":"10","key":"1562_CR15","doi-asserted-by":"publisher","first-page":"e02370","DOI":"10.1128\/mbio.02370-24","volume":"15","author":"EE Whittle","year":"2024","unstructured":"Whittle EE, Orababa O, Osgerby A, Siasat P, Element SJ, Blair JMA et al (2024) Efflux pumps mediate changes to fundamental bacterial physiology via membrane potential. Wright GD, editor. mBio 15(10):e02370-24","journal-title":"mBio"},{"issue":"Sep","key":"1562_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114542","volume":"239","author":"K Engle","year":"2022","unstructured":"Engle K, Kumar G (2022) Cancer multidrug-resistance reversal by ABCB1 inhibition: a recent update. Eur J Med Chem 239(Sep):114542","journal-title":"Eur J Med Chem"},{"issue":"2","key":"1562_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.tig.2015.11.003","volume":"32","author":"X Hu","year":"2016","unstructured":"Hu X, Zhang Z (2016) Understanding the genetic mechanisms of cancer drug resistance using genomic approaches. Trends Genet 32(2):127\u2013137","journal-title":"Trends Genet"},{"issue":"7","key":"1562_CR18","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.7150\/ijbs.72534","volume":"18","author":"A Zhang","year":"2022","unstructured":"Zhang A, Miao K, Sun H, Deng CX (2022) Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. Int J Biol Sci 18(7):3019\u20133033","journal-title":"Int J Biol Sci"},{"key":"1562_CR19","first-page":"1","volume":"2022","author":"W Long","year":"2022","unstructured":"Long W, Zhang L, Wang Y, Xie H, Wang L, Yu H (2022) Research progress and prospects of autophagy in the mechanism of multidrug resistance in tumors. Zheng D, editor. J Oncol 2022:1\u201315","journal-title":"J Oncol"},{"issue":"12","key":"1562_CR20","volume":"5","author":"FU Vaidya","year":"2022","unstructured":"Vaidya FU, Sufiyan Chhipa A, Mishra V, Gupta VK, Rawat SG, Kumar A et al (2022) Molecular and cellular paradigms of multidrug resistance in cancer. Cancer Rep 5(12):e1291","journal-title":"Cancer Rep"},{"key":"1562_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108488","volume":"249","author":"J Dong","year":"2023","unstructured":"Dong J, Yuan L, Hu C, Cheng X, Qin JJ (2023) Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): an updated review. Pharmacol Ther 249:108488","journal-title":"Pharmacol Ther"},{"issue":"2","key":"1562_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3390\/molecules28020495","volume":"28","author":"J Huang","year":"2023","unstructured":"Huang J, Ecker GF (2023) A structure-based view on ABC-transporter linked to multidrug resistance. Molecules 28(2):495","journal-title":"Molecules"},{"key":"1562_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.101011","volume":"71","author":"CP Wu","year":"2023","unstructured":"Wu CP, Hsiao SH, Wu YS (2023) Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2. Drug Resist Updat 71:101011","journal-title":"Drug Resist Updat"},{"issue":"Dec","key":"1562_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100795","volume":"59","author":"KM Hanssen","year":"2021","unstructured":"Hanssen KM, Haber M, Fletcher JI (2021) Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: beyond pharmacological inhibition. Drug Resist Updat 59(Dec):100795","journal-title":"Drug Resist Updat"},{"issue":"3","key":"1562_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/onc.2016.206","volume":"36","author":"F Di Virgilio","year":"2017","unstructured":"Di Virgilio F, Adinolfi E (2017) Extracellular purines, purinergic receptors and tumor growth. Oncogene 36(3):293\u2013303","journal-title":"Oncogene"},{"issue":"4","key":"1562_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11302-013-9372-5","volume":"9","author":"G Burnstock","year":"2013","unstructured":"Burnstock G, Di Virgilio F (2013) Purinergic signalling and cancer. Purinergic Signal 9(4):491\u2013540","journal-title":"Purinergic Signal"},{"issue":"9","key":"1562_CR27","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.1021\/acs.chemrev.0c00659","volume":"121","author":"T Kroll","year":"2021","unstructured":"Kroll T, Prescher M, Smits SHJ, Schmitt L (2021) Structure and function of hepatobiliary ATP binding cassette transporters. Chem Rev 121(9):5240\u20135288","journal-title":"Chem Rev"},{"issue":"7","key":"1562_CR28","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3390\/ijms18071593","volume":"18","author":"P Andreoletti","year":"2017","unstructured":"Andreoletti P, Raas Q, Gondcaille C, Cherkaoui-Malki M, Trompier D, Savary S (2017) Predictive structure and topology of peroxisomal ATP-binding cassette (ABC) transporters. Int J Mol Sci 18(7):1593","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1562_CR29","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/ijms23010362","volume":"23","author":"L Mora Lagares","year":"2021","unstructured":"Mora Lagares L, P\u00e9rez-Castillo Y, Minovski N, Novi\u010d M (2021) Structure\u2013function relationships in the human P-glycoprotein (ABCB1): insights from molecular dynamics simulations. Int J Mol Sci 23(1):362","journal-title":"Int J Mol Sci"},{"key":"1562_CR30","doi-asserted-by":"publisher","unstructured":"Alam A, K\u00fcng R, Kowal J, McLeod RA, Tremp N, Broude EV, et al. Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1. Proc Natl Acad Sci [Internet]. 2018 Feb 27 [cited 2025 Jun 26];115(9). Available from: https:\/\/pnas.org\/doi\/full\/https:\/\/doi.org\/10.1073\/pnas.1717044115","DOI":"10.1073\/pnas.1717044115"},{"issue":"11","key":"1562_CR31","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.1111\/jcmm.13810","volume":"22","author":"CE Dunk","year":"2018","unstructured":"Dunk CE, Pappas JJ, Lye P, Kibschull M, Javam M, Bloise E et al (2018) P-glycoprotein (P-gp)\/ ABCB 1 plays a functional role in extravillous trophoblast ( EVT ) invasion and is decreased in the pre-eclamptic placenta. J Cell Mol Med 22(11):5378\u20135393","journal-title":"J Cell Mol Med"},{"issue":"9","key":"1562_CR32","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1080\/17425255.2021.1951223","volume":"17","author":"L Gaohua","year":"2021","unstructured":"Gaohua L, Miao X, Dou L (2021) Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity. Expert Opin Drug Metab Toxicol 17(9):1103\u20131124","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"1562_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e09777","volume":"8","author":"II Ahmed Juvale","year":"2022","unstructured":"Ahmed Juvale II, Abdul Hamid AA, Abd Halim KB, Che Has AT (2022) P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease. Heliyon 8(6):e09777","journal-title":"Heliyon"},{"issue":"13","key":"1562_CR34","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.2174\/1381612826666200318130625","volume":"26","author":"I De Trizio","year":"2020","unstructured":"De Trizio I, Errede M, d\u2019Amati A, Girolamo F, Virgintino D (2020) Expression of P-gp in glioblastoma: what we can learn from brain development. Curr Pharm Des 26(13):1428\u20131437","journal-title":"Curr Pharm Des"},{"issue":"1","key":"1562_CR35","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","volume":"455","author":"RL Juliano","year":"1976","unstructured":"Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta BBA - Biomembr 455(1):152\u2013162","journal-title":"Biochim Biophys Acta BBA - Biomembr"},{"issue":"13","key":"1562_CR36","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1007\/s00259-023-06363-5","volume":"50","author":"P Mossel","year":"2023","unstructured":"Mossel P, Arif WM, De Souza GS, Varela LG, Van Der Weijden CWJ, Boersma HH et al (2023) Quantification of P-glycoprotein function at the human blood-brain barrier using [18F]MC225 and PET. Eur J Nucl Med Mol Imaging 50(13):3917\u20133927","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1562_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/bdd.2331","volume":"44","author":"B Cox","year":"2023","unstructured":"Cox B, Nicola\u00ef J, Williamson B (2023) The role of the efflux transporter, P-glycoprotein, at the blood\u2013brain barrier in drug discovery. Biopharm Drug Dispos 44(1):113\u2013126","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"1562_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12987-021-00245-4","volume":"18","author":"Y Ding","year":"2021","unstructured":"Ding Y, Zhong Y, Baldeshwiler A, Abner EL, Bauer B, Hartz AMS (2021) Protecting P-glycoprotein at the blood\u2013brain barrier from degradation in an Alzheimer\u2019s disease mouse model. Fluids Barriers CNS 18(1):10","journal-title":"Fluids Barriers CNS"},{"key":"1562_CR39","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.semcancer.2018.09.007","volume":"58","author":"J Bal\u00e7a-Silva","year":"2019","unstructured":"Bal\u00e7a-Silva J, Matias D, Carmo AD, Sarmento-Ribeiro AB, Lopes MC, Moura-Neto V (2019) Cellular and molecular mechanisms of glioblastoma malignancy: implications in resistance and therapeutic strategies. Semin Cancer Biol 58:130\u2013141","journal-title":"Semin Cancer Biol"},{"key":"1562_CR40","doi-asserted-by":"crossref","unstructured":"Bloise E, Matthews SG (2019) Multidrug resistance P-glycoprotein (P-gp), glucocorticoids, and the stress response. In Stress: physiology, biochemistry, and pathology. Academic Press, pp 227\u2013241","DOI":"10.1016\/B978-0-12-813146-6.00019-9"},{"issue":"1","key":"1562_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-024-09957-0","volume":"52","author":"B G\u00fclave","year":"2025","unstructured":"G\u00fclave B, Lesmana A, De Lange EC, Van Hasselt JC (2025) Do P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier impact morphine brain distribution? J Pharmacokinet Pharmacodyn 52(1):11","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"10","key":"1562_CR42","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3390\/biom12101365","volume":"12","author":"Y Lugones","year":"2022","unstructured":"Lugones Y, Loren P, Salazar LA (2022) Cisplatin resistance: genetic and epigenetic factors involved. Biomolecules 12(10):1365","journal-title":"Biomolecules"},{"issue":"6","key":"1562_CR43","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.2741\/4847","volume":"25","author":"R Nirmaladevi","year":"2020","unstructured":"Nirmaladevi R (2020) Epigenetic alterations in cancer. Front Biosci 25(6):1058\u20131109","journal-title":"Front Biosci"},{"issue":"4","key":"1562_CR44","doi-asserted-by":"publisher","first-page":"BSR20211812","DOI":"10.1042\/BSR20211812","volume":"42","author":"S Adhikari","year":"2022","unstructured":"Adhikari S, Bhattacharya A, Adhikary S, Singh V, Gadad SS, Roy S et al (2022) The paradigm of drug resistance in cancer: an epigenetic perspective. Biosci Rep 42(4):BSR20211812","journal-title":"Biosci Rep"},{"issue":"5","key":"1562_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3892\/ijo.2023.5567","volume":"63","author":"Y Tian","year":"2023","unstructured":"Tian Y, Lei Y, Wang Y, Lai J, Wang J, Xia F (2023) Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein (Review). Int J Oncol 63(5):119","journal-title":"Int J Oncol"},{"issue":"14","key":"1562_CR46","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.2174\/1389200221666200103111539","volume":"20","author":"K Shah","year":"2020","unstructured":"Shah K, Rawal RM (2020) Genetic and epigenetic modulation of drug resistance in cancer: challenges and opportunities. Curr Drug Metab 20(14):1114\u20131131","journal-title":"Curr Drug Metab"},{"issue":"11","key":"1562_CR47","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41571-020-0411-1","volume":"17","author":"RA Gatenby","year":"2020","unstructured":"Gatenby RA, Brown JS (2020) Integrating evolutionary dynamics into cancer therapy. Nat Rev Clin Oncol 17(11):675\u2013686","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1562_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2024.119878","volume":"1872","author":"AVL Marques","year":"2025","unstructured":"Marques AVL, Ruginsk BE, Prado LDO, De Lima DE, Daniel IW, Moure VR et al (2025) The association of ABC proteins with multidrug resistance in cancer. Biochimica et Biophysica Acta (BBA) 1872(2):119878","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"1562_CR49","doi-asserted-by":"crossref","unstructured":"Pokharel D, Roseblade A, Oenarto V, Lu JF, Bebawy M (2017) Proteins regulating the intercellular transfer and function of P-glycoprotein in multidrug-resistant cancer. Ecancermedicalscience 11:768","DOI":"10.3332\/ecancer.2017.768"},{"issue":"6","key":"1562_CR50","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3390\/membranes13060568","volume":"13","author":"SA Badiee","year":"2023","unstructured":"Badiee SA, Isu UH, Khodadadi E, Moradi M (2023) The alternating access mechanism in mammalian multidrug resistance transporters and their bacterial homologs. Membranes 13(6):568","journal-title":"Membranes"},{"issue":"15","key":"1562_CR51","doi-asserted-by":"publisher","first-page":"1469915","DOI":"10.3389\/fmicb.2024.1469915","volume":"27","author":"A Mahendran","year":"2024","unstructured":"Mahendran A, Orlando BJ (2024) Genome wide structural prediction of ABC transporter systems in Bacillus subtilis. Front Microbiol 27(15):1469915","journal-title":"Front Microbiol"},{"issue":"7","key":"1562_CR52","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3390\/pharmaceutics13071103","volume":"13","author":"TTL Nguyen","year":"2021","unstructured":"Nguyen TTL, Duong VA, Maeng HJ (2021) Pharmaceutical formulations with P-glycoprotein inhibitory effect as promising approaches for enhancing oral drug absorption and bioavailability. Pharmaceutics 13(7):1103","journal-title":"Pharmaceutics"},{"issue":"5","key":"1562_CR53","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1272\/jnms.JNMS.2020_87-508","volume":"87","author":"T Asano","year":"2020","unstructured":"Asano T (2020) Drug resistance in cancer therapy and the role of epigenetics. J Nippon Med Sch 87(5):244\u2013251","journal-title":"J Nippon Med Sch"},{"issue":"4","key":"1562_CR54","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1124\/dmd.113.056176","volume":"42","author":"R Callaghan","year":"2014","unstructured":"Callaghan R, Luk F, Bebawy M (2014) Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab Dispos 42(4):623\u2013631","journal-title":"Drug Metab Dispos"},{"issue":"51","key":"1562_CR55","doi-asserted-by":"publisher","first-page":"48813","DOI":"10.1021\/acsomega.3c06202","volume":"8","author":"AD Moralev","year":"2023","unstructured":"Moralev AD, Salomatina OV, Chernikov IV, Salakhutdinov NF, Zenkova MA, Markov AV (2023) A novel 3- meta -pyridine-1,2,4-oxadiazole derivative of glycyrrhetinic acid as a safe and promising candidate for overcoming P-glycoprotein-mediated multidrug resistance in tumor cells. ACS Omega 8(51):48813\u201348824","journal-title":"ACS Omega"},{"issue":"10","key":"1562_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.561936","volume":"16","author":"JI Lai","year":"2020","unstructured":"Lai JI, Tseng YJ, Chen MH, Huang CYF, Chang PMH (2020) Clinical perspective of FDA approved drugs with P-glycoprotein inhibition activities for potential cancer therapeutics. Front Oncol 16(10):561936","journal-title":"Front Oncol"},{"issue":"6428","key":"1562_CR57","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1126\/science.aav7102","volume":"363","author":"A Alam","year":"2019","unstructured":"Alam A, Kowal J, Broude E, Roninson I, Locher KP (2019) Structural insight into substrate and inhibitor discrimination by human P-glycoprotein. Science 363(6428):753\u2013756","journal-title":"Science"},{"key":"1562_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2024.114267","volume":"198","author":"D Patel","year":"2024","unstructured":"Patel D, Sethi N, Patel P, Shah S, Patel K (2024) Exploring the potential of P-glycoprotein inhibitors in the targeted delivery of anti-cancer drugs: a comprehensive review. Eur J Pharm Biopharm 198:114267","journal-title":"Eur J Pharm Biopharm"},{"issue":"23","key":"1562_CR59","doi-asserted-by":"publisher","first-page":"10645","DOI":"10.1021\/acs.jmedchem.9b00966","volume":"62","author":"JG Wise","year":"2019","unstructured":"Wise JG, Nanayakkara AK, Aljowni M, Chen G, De Oliveira MC, McCormick LA et al (2019) Optimizing targeted inhibitors of P-glycoprotein using computational and structure-guided approaches. J Med Chem 62(23):10645\u201310663","journal-title":"J Med Chem"},{"issue":"1","key":"1562_CR60","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1021\/acs.jmedchem.1c01272","volume":"65","author":"S Urgaonkar","year":"2022","unstructured":"Urgaonkar S, Nosol K, Said AM, Nasief NN, Bu Y, Locher KP et al (2022) Discovery and characterization of potent dual P-glycoprotein and CYP3A4 inhibitors: design, synthesis, Cryo-EM analysis, and biological evaluations. J Med Chem 65(1):191\u2013216","journal-title":"J Med Chem"},{"issue":"24","key":"1562_CR61","doi-asserted-by":"publisher","first-page":"6857","DOI":"10.1016\/j.bmc.2014.10.032","volume":"22","author":"L Jiao","year":"2014","unstructured":"Jiao L, Qiu Q, Liu B, Zhao T, Huang W, Qian H (2014) Design, synthesis and evaluation of novel triazole core based P-glycoprotein-mediated multidrug resistance reversal agents. Bioorg Med Chem 22(24):6857\u20136866","journal-title":"Bioorg Med Chem"},{"key":"1562_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115092","volume":"248","author":"Z Yang","year":"2023","unstructured":"Yang Z, Yang X, Li Y, Cai Y, Yu Y, Zhuang W et al (2023) Design, synthesis and biological evaluation of novel phenylfuran-bisamide derivatives as P-glycoprotein inhibitors against multidrug resistance in MCF-7\/ADR cell. Eur J Med Chem 248:115092","journal-title":"Eur J Med Chem"},{"issue":"1","key":"1562_CR63","doi-asserted-by":"publisher","first-page":"21217","DOI":"10.1038\/s41598-023-48281-4","volume":"13","author":"L Moesgaard","year":"2023","unstructured":"Moesgaard L, Pedersen ML, Uhd Nielsen C, Kongsted J (2023) Structure-based discovery of novel P-glycoprotein inhibitors targeting the nucleotide binding domains. Sci Rep 13(1):21217","journal-title":"Sci Rep"},{"key":"1562_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jare.2018.06.005","volume":"15","author":"S Hossen","year":"2019","unstructured":"Hossen S, Hossain MK, Basher MK, Mia MNH, Rahman MT, Uddin MJ (2019) Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: a review. J Adv Res 15:1\u201318","journal-title":"J Adv Res"},{"issue":"2","key":"1562_CR65","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2174\/1574892817666220713150521","volume":"18","author":"J Liu","year":"2023","unstructured":"Liu J, Li S, Wang J, Li N, Zhou J, Chen H (2023) Application of nano drug delivery system (NDDS) in cancer therapy: a perspective. Recent Pat Anti-Cancer Drug Discov 18(2):125\u2013132","journal-title":"Recent Pat Anti-Cancer Drug Discov"},{"key":"1562_CR66","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.omtn.2019.07.003","volume":"17","author":"Y Han","year":"2019","unstructured":"Han Y, Wang C, Dong Q, Chen T, Yang F, Liu Y et al (2019) Genetic interaction-based biomarkers identification for drug resistance and sensitivity in cancer cells. Mol Ther - Nucleic Acids 17:688\u2013700","journal-title":"Mol Ther - Nucleic Acids"},{"issue":"4","key":"1562_CR67","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ipha.2023.08.006","volume":"1","author":"SK Das","year":"2023","unstructured":"Das SK, Maheshwari RA, Chakraborty J, Deb Roy S, Shil D (2023) Enhancing drug related problem (DRP) management in Indian healthcare through AI integration: an insight view. Intelligent Pharmacy 1(4):175\u2013178","journal-title":"Intelligent Pharmacy"},{"issue":"1","key":"1562_CR68","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s11671-021-03553-8","volume":"16","author":"F Rommasi","year":"2021","unstructured":"Rommasi F, Esfandiari N (2021) Liposomal nanomedicine: applications for drug delivery in cancer therapy. Nanoscale Res Lett 16(1):95","journal-title":"Nanoscale Res Lett"},{"issue":"21","key":"1562_CR69","doi-asserted-by":"publisher","first-page":"5480","DOI":"10.3390\/cancers13215480","volume":"13","author":"M McFadden","year":"2021","unstructured":"McFadden M, Singh SK, Oprea-Ilies G, Singh R (2021) Nano-based drug delivery and targeting to overcome drug resistance of ovarian cancers. Cancers 13(21):5480","journal-title":"Cancers"},{"key":"1562_CR70","doi-asserted-by":"publisher","unstructured":"Alavi M, Hamidi M. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab Pers Ther [Internet]. 2019 Mar 26 [cited 2025 Jun 27];34(1). Available from: https:\/\/www.degruyter.com\/document\/doi\/https:\/\/doi.org\/10.1515\/dmpt-2018-0032\/html","DOI":"10.1515\/dmpt-2018-0032\/html"},{"issue":"9","key":"1562_CR71","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.3390\/pharmaceutics14091972","volume":"14","author":"OC Adekoya","year":"2022","unstructured":"Adekoya OC, Adekoya GJ, Sadiku ER, Hamam Y, Ray SS (2022) Application of DFT calculations in designing polymer-based drug delivery systems: an overview. Pharmaceutics 14(9):1972","journal-title":"Pharmaceutics"},{"key":"1562_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.progpolymsci.2019.101164","volume":"99","author":"A Zhang","year":"2019","unstructured":"Zhang A, Jung K, Li A, Liu J, Boyer C (2019) Recent advances in stimuli-responsive polymer systems for remotely controlled drug release. Prog Polym Sci 99:101164","journal-title":"Prog Polym Sci"},{"key":"1562_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121931","volume":"624","author":"H Zhang","year":"2022","unstructured":"Zhang H, Yu J, Ma L, Zhao Y, Xu S, Shi J et al (2022) Reversing multi-drug resistance by polymeric metformin to enhance antitumor efficacy of chemotherapy. Int J Pharm 624:121931","journal-title":"Int J Pharm"},{"key":"1562_CR74","doi-asserted-by":"publisher","unstructured":"Nangare S, Patil P, Patil A, Deshmukh P, Powar T, Pantwalawalkar J, et al. Pharmacokinetics of drug-in-polymer matrix-based nanoparticulate drug delivery system. In: Patel JK, Pathak YV, editors. Pharmacokinetics and pharmacodynamics of nanoparticulate drug delivery systems [Internet]. Cham: Springer International Publishing; 2022 [cited 2025 Jun 28]. p. 159\u201386. Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/978-3-030-83395-4_9","DOI":"10.1007\/978-3-030-83395-4_9"},{"key":"1562_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100777","volume":"58","author":"Z Su","year":"2021","unstructured":"Su Z, Dong S, Zhao SC, Liu K, Tan Y, Jiang X et al (2021) Novel nanomedicines to overcome cancer multidrug resistance. Drug Resist Updat 58:100777","journal-title":"Drug Resist Updat"},{"issue":"12","key":"1562_CR76","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.3390\/molecules26123610","volume":"26","author":"J Yu","year":"2021","unstructured":"Yu J, Qiu H, Yin S, Wang H, Li Y (2021) Polymeric drug delivery system based on pluronics for cancer treatment. Molecules 26(12):3610","journal-title":"Molecules"},{"issue":"3","key":"1562_CR77","doi-asserted-by":"publisher","first-page":"993","DOI":"10.7150\/thno.104872","volume":"15","author":"J Liu","year":"2025","unstructured":"Liu J, Li X, Li Y, Gong Q, Luo K (2025) Metformin-based nanomedicines for reprogramming tumor immune microenvironment. Theranostics 15(3):993\u20131016","journal-title":"Theranostics"},{"issue":"1","key":"1562_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01668-1","volume":"9","author":"X Li","year":"2024","unstructured":"Li X, Peng X, Zoulikha M, Boafo GF, Magar KT, Ju Y et al (2024) Multifunctional nanoparticle-mediated combining therapy for human diseases. Signal Transduct Target Ther 9(1):1","journal-title":"Signal Transduct Target Ther"},{"key":"1562_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtcomm.2023.105318","volume":"34","author":"MS Attia","year":"2023","unstructured":"Attia MS, Elsebaey MT, Yahya G, Chopra H, Marzouk MA, Yahya A et al (2023) Pharmaceutical polymers and P-glycoprotein: current trends and possible outcomes in drug delivery. Mater Today Commun 34:105318","journal-title":"Mater Today Commun"},{"key":"1562_CR80","doi-asserted-by":"publisher","first-page":"103526","DOI":"10.1016\/j.jddst.2022.103526","volume":"74","author":"R Kumar","year":"2022","unstructured":"Kumar R, Dkhar DS, Kumari R, Divya MS, Dubey VK et al (2022) Lipid based nanocarriers: production techniques, concepts, and commercialization aspect. J Drug Deliv Sci Technol 74:103526","journal-title":"J Drug Deliv Sci Technol"},{"key":"1562_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216220","volume":"565","author":"DN Moholkar","year":"2023","unstructured":"Moholkar DN, Kandimalla R, Gupta RC, Aqil F (2023) Advances in lipid-based carriers for cancer therapeutics: liposomes, exosomes and hybrid exosomes. Cancer Lett 565:216220","journal-title":"Cancer Lett"},{"key":"1562_CR82","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jconrel.2017.12.016","volume":"271","author":"T Date","year":"2018","unstructured":"Date T, Nimbalkar V, Kamat J, Mittal A, Mahato RI, Chitkara D (2018) Lipid-polymer hybrid nanocarriers for delivering cancer therapeutics. J Control Release 271:60\u201373","journal-title":"J Control Release"},{"issue":"3","key":"1562_CR83","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1177\/1534735415596571","volume":"15","author":"J Song","year":"2016","unstructured":"Song J, Huang H, Xia Z, Wei Y, Yao N, Zhang L et al (2016) TPGS\/phospholipids mixed micelles for delivery of icariside II to multidrug-resistant breast cancer. Integr Cancer Ther 15(3):390\u2013399","journal-title":"Integr Cancer Ther"},{"key":"1562_CR84","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.reactfunctpolym.2018.10.012","volume":"134","author":"OS Muddineti","year":"2019","unstructured":"Muddineti OS, Rompicharla SVK, Kumari P, Bhatt H, Ghosh B, Biswas S (2019) Vitamin-E\/lipid based PEGylated polymeric micellar doxorubicin to sensitize doxorubicin-resistant cells towards treatment. React Funct Polym 134:49\u201357","journal-title":"React Funct Polym"},{"issue":"48","key":"1562_CR85","doi-asserted-by":"publisher","first-page":"84559","DOI":"10.18632\/oncotarget.19187","volume":"8","author":"J Wang","year":"2017","unstructured":"Wang J, Seebacher N, Shi H, Kan Q, Duan Z (2017) Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. Oncotarget 8(48):84559\u201384571","journal-title":"Oncotarget"},{"key":"1562_CR86","unstructured":"Hassan E, Omenogor CE. AI powered predictive healthcare: deep learning for early diagnosis, personalized treatment, and disease prevention"},{"issue":"1","key":"1562_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01565-1","volume":"21","author":"SC Selvakumar","year":"2022","unstructured":"Selvakumar SC, Preethi KA, Ross K, Tusubira D, Khan MWA, Mani P et al (2022) CRISPR\/Cas9 and next generation sequencing in the personalized treatment of cancer. Mol Cancer 21(1):83","journal-title":"Mol Cancer"},{"issue":"14","key":"1562_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143421","volume":"13","author":"J Ancel","year":"2021","unstructured":"Ancel J, Perotin JM, Dewolf M, Launois C, Mulette P, Nawrocki-Raby B et al (2021) Hypoxia in lung cancer management: a translational approach. Cancers (Basel) 13(14):3421","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1562_CR89","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.trecan.2023.08.010","volume":"10","author":"K Zhang","year":"2024","unstructured":"Zhang K, Fu R, Liu R, Su Z (2024) Circulating cell-free DNA-based multi-cancer early detection. Trends Cancer 10(2):161\u2013174","journal-title":"Trends Cancer"},{"issue":"4","key":"1562_CR90","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3390\/cancers14041090","volume":"14","author":"L Pavl\u00edkov\u00e1","year":"2022","unstructured":"Pavl\u00edkov\u00e1 L, \u0160ere\u0161 M, Breier A, Sulov\u00e1 Z (2022) The roles of microRNAs in cancer multidrug resistance. Cancers 14(4):1090","journal-title":"Cancers"},{"key":"1562_CR91","doi-asserted-by":"crossref","unstructured":"Hon KW, Othman N, Hanif EA, Nasir SN, Abd Razak NS, Jamal R, Abu N (2020) Predictive biomarkers of drug resistance in colorectal cancer\u2014recent updates. In: Drug resistance in colorectal cancer: molecular mechanisms and therapeutic strategies. Academic Press,\u00a0pp 135\u2013151","DOI":"10.1016\/B978-0-12-819937-4.00008-X"},{"key":"1562_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2019.100662","volume":"48","author":"A Tolios","year":"2020","unstructured":"Tolios A, De Las Rivas J, Hovig E, Trouillas P, Scorilas A, Mohr T (2020) Computational approaches in cancer multidrug resistance research: identification of potential biomarkers, drug targets and drug-target interactions. Drug Resist Updat 48:100662","journal-title":"Drug Resist Updat"},{"key":"1562_CR93","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ejmech.2018.10.001","volume":"162","author":"Y Cao","year":"2019","unstructured":"Cao Y, Li Z, Mao L, Cao H, Kong J, Yu B et al (2019) The use of proteomic technologies to study molecular mechanisms of multidrug resistance in cancer. Eur J Med Chem 162:423\u2013434","journal-title":"Eur J Med Chem"},{"issue":"12","key":"1562_CR94","doi-asserted-by":"publisher","first-page":"e1056","DOI":"10.1016\/S2666-5247(23)00284-7","volume":"4","author":"DM Muloi","year":"2023","unstructured":"Muloi DM, Jauneikaite E, Anjum MF, Essack SY, Singleton DA, Kasudi MR et al (2023) Exploiting genomics for antimicrobial resistance surveillance at One Health interfaces. Lancet Microbe 4(12):e1056\u2013e1062","journal-title":"Lancet Microbe"},{"issue":"1","key":"1562_CR95","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.yamp.2023.07.006","volume":"6","author":"SA Turner","year":"2023","unstructured":"Turner SA, Muthusamy S (2023) Minimal residual disease testing in solid tumors. Adv Mol Pathol 6(1):139\u2013148","journal-title":"Adv Mol Pathol"},{"issue":"1","key":"1562_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-022-00348-2","volume":"27","author":"M Vaghari-Tabari","year":"2022","unstructured":"Vaghari-Tabari M, Hassanpour P, Sadeghsoltani F, Malakoti F, Alemi F, Qujeq D et al (2022) CRISPR\/Cas9 gene editing: a new approach for overcoming drug resistance in cancer. Cell Mol Biol Lett 27(1):49","journal-title":"Cell Mol Biol Lett"},{"issue":"4","key":"1562_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040842","volume":"12","author":"AJ Petty","year":"2020","unstructured":"Petty AJ, Heyman B, Yang Y (2020) Chimeric antigen receptor cell therapy: overcoming obstacles to battle cancer. Cancers (Basel) 12(4):842","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1562_CR98","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.7150\/ijbs.70120","volume":"18","author":"YH Yang","year":"2022","unstructured":"Yang YH, Liu JW, Lu C, Wei JF (2022) CAR-T cell therapy for breast cancer: from basic research to clinical application. Int J Biol Sci 18(6):2609\u20132626","journal-title":"Int J Biol Sci"},{"key":"1562_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119337","volume":"274","author":"MA Subhan","year":"2021","unstructured":"Subhan MA, Attia SA, Torchilin VP (2021) Advances in siRNA delivery strategies for the treatment of MDR cancer. Life Sci 274:119337","journal-title":"Life Sci"},{"issue":"12","key":"1562_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.656364","volume":"27","author":"K Khalaf","year":"2021","unstructured":"Khalaf K, Hana D, Chou JTT, Singh C, Mackiewicz A, Kaczmarek M (2021) Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front Immunol 27(12):656364","journal-title":"Front Immunol"},{"issue":"1","key":"1562_CR101","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1515\/oncologie-2023-0459","volume":"26","author":"L Meng","year":"2024","unstructured":"Meng L, Zheng Y, Liu H, Fan D (2024) The tumor microenvironment: a key player in multidrug resistance in cancer. Oncologie 26(1):41\u201358","journal-title":"Oncologie"},{"issue":"22","key":"1562_CR102","doi-asserted-by":"publisher","first-page":"16325","DOI":"10.3390\/ijms242216325","volume":"24","author":"S Ding","year":"2023","unstructured":"Ding S, Liu J, Han X, Tang M (2023) CRISPR\/Cas9-mediated genome editing in cancer therapy. Int J Mol Sci 24(22):16325","journal-title":"Int J Mol Sci"},{"key":"1562_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116825","volume":"235","author":"SA Mirzaei","year":"2019","unstructured":"Mirzaei SA, Dinmohammadi F, Alizadeh A, Elahian F (2019) Inflammatory pathway interactions and cancer multidrug resistance regulation. Life Sci 235:116825","journal-title":"Life Sci"},{"issue":"11","key":"1562_CR104","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.3390\/cancers15112912","volume":"15","author":"C Sordo-Bahamonde","year":"2023","unstructured":"Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez AP, Mart\u00ednez-P\u00e9rez A, Rodrigo JP, Garc\u00eda-Pedrero JM et al (2023) Chemo-immunotherapy: a new trend in cancer treatment. Cancers 15(11):2912","journal-title":"Cancers"},{"issue":"1","key":"1562_CR105","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12935-020-01719-5","volume":"21","author":"A Emami Nejad","year":"2021","unstructured":"Emami Nejad A, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, Esparvarinha M et al (2021) The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int 21(1):62","journal-title":"Cancer Cell Int"},{"issue":"13","key":"1562_CR106","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1177\/1535370220934038","volume":"245","author":"S Roy","year":"2020","unstructured":"Roy S, Kumaravel S, Sharma A, Duran CL, Bayless KJ, Chakraborty S (2020) Hypoxic tumor microenvironment: implications for cancer therapy. Exp Biol Med 245(13):1073\u20131086","journal-title":"Exp Biol Med"},{"issue":"7","key":"1562_CR107","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.3390\/cancers15071927","volume":"15","author":"M Ye","year":"2023","unstructured":"Ye M, Huang X, Wu Q, Liu F (2023) Senescent stromal cells in the tumor microenvironment: victims or accomplices? Cancers 15(7):1927","journal-title":"Cancers"},{"issue":"2","key":"1562_CR108","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3390\/cancers15020376","volume":"15","author":"K Dzobo","year":"2023","unstructured":"Dzobo K, Senthebane DA, Dandara C (2023) The tumor microenvironment in tumorigenesis and therapy resistance revisited. Cancers 15(2):376","journal-title":"Cancers"},{"issue":"3","key":"1562_CR109","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/pharmaceutics15030893","volume":"15","author":"K Aloss","year":"2023","unstructured":"Aloss K, Hamar P (2023) Recent preclinical and clinical progress in liposomal doxorubicin. Pharmaceutics 15(3):893","journal-title":"Pharmaceutics"},{"issue":"1","key":"1562_CR110","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/cyto.b.21737","volume":"96","author":"JF Marcelletti","year":"2019","unstructured":"Marcelletti JF, Sikic BI, Cripe LD, Paietta E (2019) Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia. Cytometry B Clin Cytom 96(1):57\u201366","journal-title":"Cytometry B Clin Cytom"},{"issue":"9","key":"1562_CR111","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.7150\/jca.18686","volume":"8","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, Mangal N, Menon R, Freise KJ, Salem AH (2017) Response rates as predictors of overall survival: a meta-analysis of acute myeloid leukemia trials. J Cancer 8(9):1562\u20131567","journal-title":"J Cancer"},{"key":"1562_CR112","doi-asserted-by":"publisher","unstructured":"Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group, editor. Cochrane Database Syst Rev [Internet]. 2013 Jul 9 [cited 2025 Jun 28];2016(9). Available from: http:\/\/doi.wiley.com\/https:\/\/doi.org\/10.1002\/14651858.CD006910.pub2","DOI":"10.1002\/14651858.CD006910.pub2"},{"issue":"6","key":"1562_CR113","volume":"1878","author":"Z Li","year":"2023","unstructured":"Li Z, Yin P (2023) Tumor microenvironment diversity and plasticity in cancer multidrug resistance. Biochim Biophys Acta BBA - Rev Cancer 1878(6):188997","journal-title":"Biochim Biophys Acta BBA - Rev Cancer"},{"key":"1562_CR114","doi-asserted-by":"publisher","first-page":"e84263","DOI":"10.7554\/eLife.84263","volume":"12","author":"J West","year":"2023","unstructured":"West J, Adler F, Gallaher J, Strobl M, Brady-Nicholls R, Brown J et al (2023) A survey of open questions in adaptive therapy: bridging mathematics and clinical translation. eLife 12:e84263","journal-title":"eLife"},{"issue":"10","key":"1562_CR115","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1158\/1535-7163.MCT-15-0986","volume":"15","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Sriraman SK, Kenny HA, Luther E, Torchilin V, Lengyel E (2016) Reversal of chemoresistance in ovarian cancer by co-delivery of a P-glycoprotein inhibitor and paclitaxel in a liposomal platform. Mol Cancer Ther 15(10):2282\u20132293","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"1562_CR116","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT (2018) Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15(2):81\u201394","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1562_CR117","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1039\/C7BM01206C","volume":"6","author":"Y Peng","year":"2018","unstructured":"Peng Y, Nie J, Cheng W, Liu G, Zhu D, Zhang L et al (2018) A multifunctional nanoplatform for cancer chemo-photothermal synergistic therapy and overcoming multidrug resistance. Biomater Sci 6(5):1084\u20131098","journal-title":"Biomater Sci"},{"issue":"8","key":"1562_CR118","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/COC.0000000000001014","volume":"46","author":"PM Fracasso","year":"2023","unstructured":"Fracasso PM, Fisher GA, Goodner SA, Beumer JH, Egorin MJ, Fears CL et al (2023) A phase I trial of the ABCB1 inhibitor, oral valspodar, in combination with paclitaxel in patients with advanced solid tumors. Am J Clin Oncol 46(8):353\u2013359","journal-title":"Am J Clin Oncol"},{"key":"1562_CR119","doi-asserted-by":"publisher","first-page":"891652","DOI":"10.3389\/fonc.2022.891652","volume":"12","author":"TB Emran","year":"2022","unstructured":"Emran TB, Shahriar A, Mahmud AR, Rahman T, Abir MH, Siddiquee Mohd FR et al (2022) Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches. Front Oncol 12:891652","journal-title":"Front Oncol"},{"key":"1562_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.imu.2022.100965","volume":"31","author":"Z Dlamini","year":"2022","unstructured":"Dlamini Z, Skepu A, Kim N, Mkhabele M, Khanyile R, Molefi T et al (2022) AI and precision oncology in clinical cancer genomics: from prevention to targeted cancer therapies-an outcomes based patient care. Inf Med Unlocked 31:100965","journal-title":"Inf Med Unlocked"},{"issue":"10","key":"1562_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.588221","volume":"14","author":"N Biswas","year":"2020","unstructured":"Biswas N, Chakrabarti S (2020) Artificial intelligence (AI)-based systems biology approaches in multi-omics data analysis of cancer. Front Oncol 14(10):588221","journal-title":"Front Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01562-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01562-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01562-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:04:19Z","timestamp":1760195059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01562-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":121,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1562"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01562-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}